Critical Pharmacodynamic Warning

Meropenem affects the metabolic pathway.

When patients take Meropenem concurrently with drugs metabolized by , the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.

Clinical Overview for Meropenem

This page outlines known interaction pathways involving Meropenem, focusing primarily on its profile as a affecting the pathway.

Enzyme Interaction Profile

Meropenem demonstrates potency against . Clinical significance of this interaction requires further evaluation.

Inhibitor

A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.

Clinical Example: Meropenem affects

Inducer

A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.

Interaction Details
Drug Name Meropenem
Affected Enzyme
Inhibitor Strength Unknown
Inducers No inducers listed
Inhibitors No inhibitors listed
Clinical Recommendations

Consult primary literature for guidance.

Monitoring Parameters:
  • Therapeutic drug levels
  • Adverse effect monitoring
  • Clinical response assessment
Dose Considerations:
  • Consider dose reduction
  • Evaluate alternative therapies
  • Adjust based on response
Quick Facts
Interaction ID
14094
Primary Pathway
Interaction Type
Enzyme Inhibition
Clinical Phase
Unknown
Clinical Significance

Clinical significance requires further evaluation.

Information Sources
  • FDA Drug Interaction Database
  • Clinical Pharmacology Guidelines
  • Pharmaceutical Labeling Information
  • Published Clinical Studies

Last updated: August 5, 2026